Targeting Intracellular Signaling Molecules in the Pursuit of Disease Remission and Comorbid Management of Patients with Rheumatoid Arthritis

REGISTER NOW!
Already Registered?
SIGN IN

WEBCAST DATE

Wednesday, March 27, 2019

6:00 PM Eastern    5:00 PM Central    4:00 PM Mountain    3:00 PM Pacific

PROGRAM FEATURES

• Virtual Reality headsets provided to all attendees for viewing this presentation only
• Interactive, case-based learning environment
• Create your own Personalized Poster
• iPads provided to enhance learning experience and enable real-time Q&A

PROGRAM CHAIR

Maria Greenwald, MD, FACR
MAVEN Rheumatology Consultant
Medical Director, Desert Medical Advances
Palm Desert, CA

FACULTY

Andreas Reimold, MD
Professor
Rheumatic Diseases Division
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

AGENDA

I. A chronic inflammatory Disease-Rheumatoid arthritis
  a. Biological pathways that result in pathology

II. JAK/STAT pathway inhibition—molecular and pharmacodynamics effects
  a. Blockade of the JAK/STAT pathway
  b. JAK inhibitors—profiling their specificity

III. Clinical trials review of approved JAK inhibitors—application in the patient care setting
  a. Tofacitinib data review in moderate-to-severe RA
  b. Baricitinib data review in moderate-to-severe RA
  c. Up and coming agents
  d. Comorbid considerations and selective JAK inhibition in RA
  e. Monitoring for achievement of treatment agents

IV. Conclusion and Q&A

TARGET AUDIENCE

This activity is designed to meet the educational needs of rheumatologists, internists, and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.

LEARNING OBJECTIVES

After completing the educational activity, learners should be better able to:

• Review the systemic pathogenesis of rheumatoid arthritis as driven by inflammatory effector pathways
• Discuss the clinical trials data for the efficacy and safety of JAK pathway inhibition in the treatment of moderate-to-severe rheumatoid arthritis
• Describe the disease-related comorbid changes, their associated risks and management in patients with rheumatoid arthritis

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity is planned and produced in accordance with ACCME Essentials.
 

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with rheumatoid arthritis.

CNE Credits:1.5 ANCC Contact Hour(s)

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.